-
1
-
-
0035810142
-
Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome
-
COI: 1:CAS:528:DC%2BD3MXivFGnu7o%3D, PID: 11287973
-
Druker, B.J., et al., Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med, 2001. 344(14): p. 1038-1042.
-
(2001)
N Engl J Med
, vol.344
, Issue.14
, pp. 1038-1042
-
-
Druker, B.J.1
-
2
-
-
20044366163
-
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma
-
COI: 1:CAS:528:DC%2BD2MXit1Wksbk%3D, PID: 15758009
-
Stupp, R., et al., Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med, 2005. 352(10): p. 987-996.
-
(2005)
N Engl J Med
, vol.352
, Issue.10
, pp. 987-996
-
-
Stupp, R.1
-
3
-
-
84891785971
-
Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial
-
COI: 1:CAS:528:DC%2BC3sXhvFSksrbF, PID: 24101040
-
Gilbert, M.R., et al., Dose-dense temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol, 2013. 31(32): p. 4085-4091.
-
(2013)
J Clin Oncol
, vol.31
, Issue.32
, pp. 4085-4091
-
-
Gilbert, M.R.1
-
4
-
-
0032767387
-
Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials
-
COI: 1:STN:280:DC%2BD3c%2FjtVSmsQ%3D%3D, PID: 10561324
-
Wong, E.T., et al., Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials. J Clin Oncol, 1999. 17(8): p. 2572.
-
(1999)
J Clin Oncol
, vol.17
, Issue.8
, pp. 2572
-
-
Wong, E.T.1
-
5
-
-
44849138808
-
Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas
-
PID: 18356283
-
Lamborn, K.R., et al., Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol, 2008. 10(2): p. 162-170.
-
(2008)
Neuro Oncol
, vol.10
, Issue.2
, pp. 162-170
-
-
Lamborn, K.R.1
-
6
-
-
41649112610
-
Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence
-
COI: 1:CAS:528:DC%2BD1cXitlyqs7o%3D, PID: 18316689
-
Norden, A., et al., Bevacizumab for recurrent malignant gliomas: efficacy, toxicity, and patterns of recurrence. Neurology, 2008. 70(10): p. 779-787.
-
(2008)
Neurology
, vol.70
, Issue.10
, pp. 779-787
-
-
Norden, A.1
-
7
-
-
0033897173
-
A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse
-
COI: 1:CAS:528:DC%2BD3cXmvVCgsrs%3D, PID: 10944597
-
Yung, W.K., et al., A phase II study of temozolomide vs. procarbazine in patients with glioblastoma multiforme at first relapse. Br J Cancer, 2000. 83(5): p. 588-593.
-
(2000)
Br J Cancer
, vol.83
, Issue.5
, pp. 588-593
-
-
Yung, W.K.1
-
8
-
-
84894114159
-
A randomized trial of bevacizumab for newly diagnosed glioblastoma
-
COI: 1:CAS:528:DC%2BC2cXjt1alu7o%3D, PID: 24552317
-
Gilbert, M.R., et al., A randomized trial of bevacizumab for newly diagnosed glioblastoma. N Engl J Med, 2014. 370(8): p. 699-708.
-
(2014)
N Engl J Med
, vol.370
, Issue.8
, pp. 699-708
-
-
Gilbert, M.R.1
-
9
-
-
84894194756
-
Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma
-
COI: 1:CAS:528:DC%2BC2cXjt1alu7s%3D, PID: 24552318
-
Chinot, O.L., et al., Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med, 2014. 370(8): p. 709-722.
-
(2014)
N Engl J Med
, vol.370
, Issue.8
, pp. 709-722
-
-
Chinot, O.L.1
-
10
-
-
84908563697
-
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial
-
COI: 1:CAS:528:DC%2BC2cXhsVSmt73E, PID: 25163906
-
Stupp, R., et al., Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol, 2014. 15(10): p. 1100-1108.
-
(2014)
Lancet Oncol
, vol.15
, Issue.10
, pp. 1100-1108
-
-
Stupp, R.1
-
11
-
-
54549108740
-
-
Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature, 2008. 455(7216): p. 1061-1068.
-
(2008)
Nature
, vol.455
, Issue.7216
, pp. 1061-1068
-
-
-
12
-
-
84942319120
-
Spatiotemporal evolution of the primary glioblastoma genome
-
COI: 1:CAS:528:DC%2BC2MXhsFShsLnM, PID: 26373279
-
Kim, J., et al., Spatiotemporal evolution of the primary glioblastoma genome. Cancer Cell, 2015. 28(3): p. 318-328.
-
(2015)
Cancer Cell
, vol.28
, Issue.3
, pp. 318-328
-
-
Kim, J.1
-
13
-
-
79958849271
-
Heterogeneity maintenance in glioblastoma: a social network
-
COI: 1:CAS:528:DC%2BC3MXnsFKiu74%3D, PID: 21628493
-
Bonavia, R., et al., Heterogeneity maintenance in glioblastoma: a social network. Cancer Res, 2011. 71(12): p. 4055-4060.
-
(2011)
Cancer Res
, vol.71
, Issue.12
, pp. 4055-4060
-
-
Bonavia, R.1
-
14
-
-
84874598318
-
Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics
-
COI: 1:CAS:528:DC%2BC3sXltVWms7c%3D, PID: 23412337
-
Sottoriva, A., et al., Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamics. Proc Natl Acad Sci U S A, 2013. 110(10): p. 4009-4014.
-
(2013)
Proc Natl Acad Sci U S A
, vol.110
, Issue.10
, pp. 4009-4014
-
-
Sottoriva, A.1
-
15
-
-
73649123907
-
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1
-
COI: 1:CAS:528:DC%2BC3cXkvFKgsL4%3D, PID: 20129251
-
Verhaak, R.G., et al., Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell, 2010. 17(1): p. 98-110.
-
(2010)
Cancer Cell
, vol.17
, Issue.1
, pp. 98-110
-
-
Verhaak, R.G.1
-
16
-
-
35949002429
-
Malignant astrocytic glioma: genetics, biology, and paths to treatment
-
COI: 1:CAS:528:DC%2BD2sXhtlSitLrO, PID: 17974913
-
Furnari, F.B., et al., Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev, 2007. 21(21): p. 2683-2710.
-
(2007)
Genes Dev
, vol.21
, Issue.21
, pp. 2683-2710
-
-
Furnari, F.B.1
-
17
-
-
33644820339
-
Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis
-
COI: 1:CAS:528:DC%2BD28XivFWjtL4%3D, PID: 16530701
-
Phillips, H.S., et al., Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell, 2006. 9(3): p. 157-173.
-
(2006)
Cancer Cell
, vol.9
, Issue.3
, pp. 157-173
-
-
Phillips, H.S.1
-
18
-
-
84885074034
-
The somatic genomic landscape of glioblastoma
-
COI: 1:CAS:528:DC%2BC3sXhs1Srtb7J, PID: 24120142
-
Brennan, C.W., et al., The somatic genomic landscape of glioblastoma. Cell, 2013. 155(2): p. 462-477.
-
(2013)
Cell
, vol.155
, Issue.2
, pp. 462-477
-
-
Brennan, C.W.1
-
19
-
-
84872036356
-
Genetics of adult glioma
-
COI: 1:CAS:528:DC%2BC38XhvVais77J, PID: 23238284
-
Goodenberger, M.L. and R.B. Jenkins, Genetics of adult glioma. Cancer Genet, 2012. 205(12): p. 613-621.
-
(2012)
Cancer Genet
, vol.205
, Issue.12
, pp. 613-621
-
-
Goodenberger, M.L.1
Jenkins, R.B.2
-
20
-
-
84884407337
-
Tumour heterogeneity in the clinic
-
COI: 1:CAS:528:DC%2BC3sXhsVOns7fN, PID: 24048068
-
Bedard, P.L., et al., Tumour heterogeneity in the clinic. Nature, 2013. 501(7467): p. 355-364.
-
(2013)
Nature
, vol.501
, Issue.7467
, pp. 355-364
-
-
Bedard, P.L.1
-
21
-
-
84902668801
-
Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma
-
COI: 1:CAS:528:DC%2BC2cXpslygsL4%3D, PID: 24925914
-
Patel, A.P., et al., Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma. Science, 2014. 344(6190): p. 1396-1401.
-
(2014)
Science
, vol.344
, Issue.6190
, pp. 1396-1401
-
-
Patel, A.P.1
-
22
-
-
70349638289
-
Tumour-initiating cells: challenges and opportunities for anticancer drug discovery
-
COI: 1:CAS:528:DC%2BD1MXhtF2kurbL, PID: 19794444
-
Zhou, B.B., et al., Tumour-initiating cells: challenges and opportunities for anticancer drug discovery. Nat Rev Drug Discov, 2009. 8(10): p. 806-823.
-
(2009)
Nat Rev Drug Discov
, vol.8
, Issue.10
, pp. 806-823
-
-
Zhou, B.B.1
-
23
-
-
84877775048
-
Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways
-
COI: 1:CAS:528:DC%2BC3sXlt1GgtLs%3D, PID: 23331007
-
Liu, J., et al., Glioblastoma tumor initiating cells: therapeutic strategies targeting apoptosis and microRNA pathways. Curr Mol Med, 2013. 13(3): p. 352-357.
-
(2013)
Curr Mol Med
, vol.13
, Issue.3
, pp. 352-357
-
-
Liu, J.1
-
24
-
-
84923911546
-
Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution
-
COI: 1:CAS:528:DC%2BC2MXmtlWgu7s%3D, PID: 25650244
-
Kim, H., et al., Whole-genome and multisector exome sequencing of primary and post-treatment glioblastoma reveals patterns of tumor evolution. Genome Res, 2015. 25(3): p. 316-327.
-
(2015)
Genome Res
, vol.25
, Issue.3
, pp. 316-327
-
-
Kim, H.1
-
25
-
-
80053539103
-
Adjuvant trastuzumab in HER2-positive breast cancer
-
COI: 1:CAS:528:DC%2BC3MXht12mtLvN, PID: 21991949
-
Slamon, D., et al., Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med, 2011. 365(14): p. 1273-1283.
-
(2011)
N Engl J Med
, vol.365
, Issue.14
, pp. 1273-1283
-
-
Slamon, D.1
-
26
-
-
0032519431
-
Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes
-
COI: 1:CAS:528:DyaK1cXht1Wrtrc%3D, PID: 9466980
-
Iyer, L., et al., Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest, 1998. 101(4): p. 847-854.
-
(1998)
J Clin Invest
, vol.101
, Issue.4
, pp. 847-854
-
-
Iyer, L.1
-
27
-
-
84949784176
-
Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting
-
PID: 26692528
-
Lu, C.Y., et al., Clinical implication of UGT1A1 promoter polymorphism for irinotecan dose escalation in metastatic colorectal cancer patients treated with bevacizumab combined with FOLFIRI in the first-line setting. Transl Oncol, 2015. 8(6): p. 474-479.
-
(2015)
Transl Oncol
, vol.8
, Issue.6
, pp. 474-479
-
-
Lu, C.Y.1
-
28
-
-
73249126947
-
Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors
-
COI: 1:CAS:528:DC%2BC3cXotVOrtw%3D%3D, PID: 19179423
-
Armstrong, T.S., et al., Risk analysis of severe myelotoxicity with temozolomide: the effects of clinical and genetic factors. Neuro Oncol, 2009. 11(6): p. 825-832.
-
(2009)
Neuro Oncol
, vol.11
, Issue.6
, pp. 825-832
-
-
Armstrong, T.S.1
-
29
-
-
20044372154
-
MGMT gene silencing and benefit from temozolomide in glioblastoma
-
COI: 1:CAS:528:DC%2BD2MXit1Wktro%3D, PID: 15758010
-
Hegi, M.E., et al., MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med, 2005. 352(10): p. 997-1003.
-
(2005)
N Engl J Med
, vol.352
, Issue.10
, pp. 997-1003
-
-
Hegi, M.E.1
-
30
-
-
84942375312
-
The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide
-
COI: 1:CAS:528:DC%2BC28XitVCntbfN, PID: 25910840
-
Rapkins, R.W., et al., The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol, 2015. 17(12): p. 1589-1598.
-
(2015)
Neuro Oncol
, vol.17
, Issue.12
, pp. 1589-1598
-
-
Rapkins, R.W.1
-
31
-
-
84892775264
-
Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA
-
COI: 1:CAS:528:DC%2BC2cXkslOl, PID: 24310612
-
Nathanson, D.A., et al., Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science, 2014. 343(6166): p. 72-76.
-
(2014)
Science
, vol.343
, Issue.6166
, pp. 72-76
-
-
Nathanson, D.A.1
-
32
-
-
35348822482
-
Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies
-
COI: 1:CAS:528:DC%2BD2sXhtFCjt7vP, PID: 17872411
-
Stommel, J.M., et al., Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies. Science, 2007. 318(5848): p. 287-290.
-
(2007)
Science
, vol.318
, Issue.5848
, pp. 287-290
-
-
Stommel, J.M.1
-
33
-
-
77958478674
-
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer
-
COI: 1:CAS:528:DC%2BC3cXhtlWlsrrN, PID: 20966921
-
Pao, W. and J. Chmielecki, Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer, 2010. 10(11): p. 760-774.
-
(2010)
Nat Rev Cancer
, vol.10
, Issue.11
, pp. 760-774
-
-
Pao, W.1
Chmielecki, J.2
-
34
-
-
39749169093
-
Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments
-
COI: 1:CAS:528:DC%2BD1cXhvF2ntL0%3D, PID: 18281526
-
Brandes, A.A., et al., Epidermal growth factor receptor inhibitors in neuro-oncology: hopes and disappointments. Clin Cancer Res, 2008. 14(4): p. 957-960.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.4
, pp. 957-960
-
-
Brandes, A.A.1
-
35
-
-
77955911497
-
Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma
-
COI: 1:CAS:528:DC%2BC3cXhtFWmsLnM, PID: 20713517
-
Inda, M.M., et al., Tumor heterogeneity is an active process maintained by a mutant EGFR-induced cytokine circuit in glioblastoma. Genes Dev, 2010. 24(16): p. 1731-1745.
-
(2010)
Genes Dev
, vol.24
, Issue.16
, pp. 1731-1745
-
-
Inda, M.M.1
-
36
-
-
84861760527
-
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors
-
COI: 1:CAS:528:DC%2BC38XmvF2msL0%3D, PID: 22588883
-
Vivanco, I., et al., Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov, 2012. 2(5): p. 458-471.
-
(2012)
Cancer Discov
, vol.2
, Issue.5
, pp. 458-471
-
-
Vivanco, I.1
-
37
-
-
4644289313
-
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells
-
COI: 1:CAS:528:DC%2BD2cXnsFOlu7g%3D, PID: 15374980
-
Wood, E.R., et al., A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res, 2004. 64(18): p. 6652-6659.
-
(2004)
Cancer Res
, vol.64
, Issue.18
, pp. 6652-6659
-
-
Wood, E.R.1
-
38
-
-
38049018155
-
A quantitative analysis of kinase inhibitor selectivity
-
COI: 1:CAS:528:DC%2BD1cXisFGlsQ%3D%3D, PID: 18183025
-
Karaman, M.W., et al., A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol, 2008. 26(1): p. 127-132.
-
(2008)
Nat Biotechnol
, vol.26
, Issue.1
, pp. 127-132
-
-
Karaman, M.W.1
-
39
-
-
84874038379
-
A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma
-
COI: 1:CAS:528:DC%2BC3sXislOqtL0%3D, PID: 23363814
-
Reardon, D.A., et al., A phase I/II trial of pazopanib in combination with lapatinib in adult patients with relapsed malignant glioma. Clin Cancer Res, 2013. 19(4): p. 900-908.
-
(2013)
Clin Cancer Res
, vol.19
, Issue.4
, pp. 900-908
-
-
Reardon, D.A.1
-
40
-
-
33846995628
-
Economics of new oncology drug development
-
PID: 17210942
-
DiMasi, J.A. and H.G. Grabowski, Economics of new oncology drug development. J Clin Oncol, 2007. 25(2): p. 209-216.
-
(2007)
J Clin Oncol
, vol.25
, Issue.2
, pp. 209-216
-
-
DiMasi, J.A.1
Grabowski, H.G.2
-
41
-
-
52449091099
-
Designing phase 0 cancer clinical trials
-
COI: 1:CAS:528:DC%2BD1cXntlWku7s%3D, PID: 18559582
-
Murgo, A.J., et al., Designing phase 0 cancer clinical trials. Clin Cancer Res, 2008. 14(12): p. 3675-3682.
-
(2008)
Clin Cancer Res
, vol.14
, Issue.12
, pp. 3675-3682
-
-
Murgo, A.J.1
-
42
-
-
84927606243
-
Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400
-
COI: 1:CAS:528:DC%2BC2MXmtVahsr8%3D, PID: 25680375
-
Herbst, R.S., et al., Lung Master Protocol (Lung-MAP)-a biomarker-driven protocol for accelerating development of therapies for squamous cell lung cancer: SWOG S1400. Clin Cancer Res, 2015. 21(7): p. 1514-1524.
-
(2015)
Clin Cancer Res
, vol.21
, Issue.7
, pp. 1514-1524
-
-
Herbst, R.S.1
-
43
-
-
79957857433
-
The BATTLE trial: personalizing therapy for lung cancer
-
COI: 1:CAS:528:DC%2BC3MXpsVylsb0%3D, PID: 22586319
-
Kim, E.S., et al., The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov, 2011. 1(1): p. 44-53.
-
(2011)
Cancer Discov
, vol.1
, Issue.1
, pp. 44-53
-
-
Kim, E.S.1
-
44
-
-
67650652432
-
I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy
-
COI: 1:STN:280:DC%2BD1Mvis1Gjsg%3D%3D, PID: 19440188
-
Barker, A.D., et al., I-SPY 2: an adaptive breast cancer trial design in the setting of neoadjuvant chemotherapy. Clin Pharmacol Ther, 2009. 86(1): p. 97-100.
-
(2009)
Clin Pharmacol Ther
, vol.86
, Issue.1
, pp. 97-100
-
-
Barker, A.D.1
-
45
-
-
84894477310
-
Evaluating many treatments and biomarkers in oncology: a new design
-
PID: 24248692
-
Kaplan, R., et al., Evaluating many treatments and biomarkers in oncology: a new design. J Clin Oncol, 2013. 31(36): p. 4562-4568.
-
(2013)
J Clin Oncol
, vol.31
, Issue.36
, pp. 4562-4568
-
-
Kaplan, R.1
-
46
-
-
84904211802
-
Molecular analysis for therapy choice: NCI MATCH
-
PID: 25023344
-
Conley, B.A. and J.H. Doroshow, Molecular analysis for therapy choice: NCI MATCH. Semin Oncol, 2014. 41(3): p. 297-299.
-
(2014)
Semin Oncol
, vol.41
, Issue.3
, pp. 297-299
-
-
Conley, B.A.1
Doroshow, J.H.2
|